CLL | Tumor

CURE’s Chronic Lymphocytic Leukemia (CLL) page features the latest cancer news and updates on CLL Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in chronic lymphocytic leukemia.

Drug Duo Shows Promise in Treating Chronic Lymphocytic Leukemia

April 13th 2018

A new drug combination bested current standard of care in a clinical trial.

Duvelisib Granted Priority Review for CLL and Follicular Lymphoma

April 9th 2018

The Food and Drug Administration (FDA) granted duvelisib a priority review to a new drug application (NDA) for full approval to treat patients who have relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia (CLL/SLL). The FDA also granted an accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma.

Patients With CLL Are Willing to Trade Efficacy for Less Severe Side Effects

March 4th 2018

Survey finds quality of life and cost affect treatment decisions.

Combining and Sequencing Agents in CLL

January 30th 2018

William G. Wierda, M.D., Ph.D., medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses how to best combine and sequence therapies for patients with chronic lymphocytic leukemia (CLL).

CLL-Specific Society Fills Unmet Need

December 26th 2017

The CLL Society is a nonprofit organization that serves the CLL community by offering a platform for patients and caregivers to receive education and support, as well as information on cutting-edge research and treatment options.

CLL Survivors Worried About Life Expectancy, Quality of Life

December 25th 2017

While patients with chronic lymphocytic leukemia (CLL) tend to have long life expectancies, with many prescribed to a “watch-and-wait” approach, a recent study by the Cancer Support Community (CSC) found that more than half of patients living with the disease reported that having CLL affects their viewpoints regarding their life expectancy.

Examining the Safety of CLL Medication

September 25th 2017

OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include Imbruvica (ibrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor; Venclexta (venetoclax), a B-cell lymphoma-2 (BCL2) inhibitor; and Zydelig (idelalisib), a phosphoinositide 3-kinase (PI3K) inhibitor.

Drug Provides High Response Rate in CLL

September 25th 2017

Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the agent led to negative minimal residual disease (MRD) in 40 percent of patients involved.

A Personalized Era in Chronic Lymphocytic Leukemia Treatment

September 18th 2017

Researchers are identifying targets to treat chronic lymphocytic leukemia.

Expert Discusses Advances in Treating CLL

June 13th 2017

Imbruvica (ibrutinib) continues to demonstrate benefit in patients with chronic lymphocytic leukemia (CLL) who had at least one prior therapy, according to a four-year follow-up of the RESONATE study, which compared the BTK inhibitor to Arzerra (ofatumumab).

The Final Chemo Cycle

February 27th 2017

As Ed completes his final chemo cycle, he loses a friend.

Expert Answers: What's the Best Frontline Treatment for Chronic Lymphocytic Leukemia

November 26th 2016

Having multiple options for frontline treatment of CLL may be better than deciding on one standard, an expert says.

Change is on the Horizon for CLL Treatment, Expert Says

November 23rd 2016

The treatment landscape for chronic lymphocytic leukemia (CLL) is going to drastically change over the next decade or so, says Jose Leis, M.D.

New Agents on Horizon in CLL, Though Advantages Are Not Yet Clear

September 16th 2016

Novel therapeutic agents have been developed for chronic lymphocytic leukemia (CLL), but their advantage over traditional treatments for this type of cancer have yet to be proved.

Frontline Treatment for Chronic Lymphocytic Leukemia Not One-Size-Fits-All

September 9th 2016

There are now more personalized treatment options for patients with CLL.

Arzerra Combination FDA Approved in Chronic Lymphocytic Leukemia

August 31st 2016

Arzerra was approved in combination with fludarabine and cyclophosphamide to treat patients with CLL.

The Changing Treatment Landscape of Chronic Lymphocytic Leukemia

July 26th 2016

As new therapies get approved and continue to be investigated, treatment for CLL is rapidly evolving.

FDA Updates Label of Imbruvica to Affirm Efficacy in Chronic Lymphocytic Leukemia

May 10th 2016

The FDA expanded the label for Imbruvica for some patients with CLL, as the drug continues to show improved survival benefits.

FDA Approves Venclexta for CLL

April 11th 2016

The FDA approved Venclexta for patients with CLL who have a 17p deletion and failed at least one prior therapy.

New Developments Provide Answers, Raise New Questions in Chronic Lymphocytic Leukemia

April 5th 2016

The treatment landscape of chronic lymphocytic leukemia is rapidly evolving, according to Jeffrey Jones, an assistant professor at The Ohio State University Comprehensive Cancer Center.

Recent Imbruvica Approval Signifies CLL is Progressing Towards a Cure

April 1st 2016

The landscape for treating CLL is changing, bringing about questions and hope for a cure.

Recognizing Side Effects in Novel Treatments for CLL Can Be Crucial

March 18th 2016

Patients taking novel treatments for CLL, and their caregivers, should know which side effects to expect — and recognize when they become emergencies.

FDA Approves Imbruvica for Frontline Treatment of CLL

March 5th 2016

In the phase 3 RESONATE-2 study, Imbruvica improved progression-free survival (PFS) by 84 percent in previously untreated patients with CLL or SLL.

FDA Approves Extended Therapy With Arzerra for Chronic Lymphocytic Leukemia

January 19th 2016

The approval was based on a near doubling in progression-free survival (PFS) seen with the treatment compared with observation in the phase 3 PROLONG trial.

Whispering Hope: Treatment for CLL

January 19th 2016

Ed chronicles part II of his chronic lymphocytic leukemia (CLL) story from the third person.

New Agent Shows Promise Over Imbruvica in Treatment of CLL

January 8th 2016

In an interview with CURE, John C. Byrd discusses the efficacy of acalabrutinib and how it compares with Imbruvica.

Next-Generation Drug Challenging Imbruvica in Chronic Lymphocytic Leukemia

December 11th 2015

Less than two years after Imbruvica gained approval for patients with CLL, a second-generation agent has demonstrated a 95 percent response rate.

Frontline Imbruvica Improves Survival in Chronic Lymphocytic Leukemia

December 8th 2015

The results showed a two-year overall survival rate of 98 percent with Imbruvica.

William G. Wierda on the Treatment of CLL

December 1st 2015

CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.

Gaining a Fuller Understanding of Neurotoxicity From CAR T Cell Therapy

November 24th 2015

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.